Sarepta Therapeutics Cash Flow - Annual (NASDAQ:SRPT)

Add to My Stocks
$30.38 $1.7 (5.93%) SRPT stock closing price Feb 22, 2017 (Closing)

The financial analysis of SRPT requires an investor to check the cash flows for Sarepta Therapeutics. While its important to look at the Sarepta Therapeutics debt position, the cash flow statement becomes equally important because public companies use accrual accounting. For example, if a company sells a product which gets counted as Sarepta Therapeutics revenue but does not convert to cash because it does not receive payment in the same quarter, it affects the cash position for that period. Sarepta Therapeutics had cash and cash equivalents of $73.55M at beginning of year and $80.3M at year end for 2015. Sarepta Therapeutics cash flow analysis tells whether or not the company has enough cash for its day to day activities, and for investing for future growth. Sarepta Therapeutics has a positive cash and cash equivalents change of $6.75M. View details of Sarepta Therapeutics cash flows for latest & last ten financial years.

show more
View Previous Years
View Next Years
Fiscal year is Jan - Dec. 2015 2014 2013 2012 2011 2010 2009 2008 2007
Sarepta Therapeutics Net Income Cash Flow
Depreciation Depletion Amortization Cash-Flow5.89M6.12M1.27M1.52M1.3M1.46M1.37M1.46M2.01M
Net Increase (Decrease) in Assets Liabilities31.98M-22.13M12.26M-5.3M6.93M-0.35M2.93M-2.82M-0.35M
Cash From (used in) Discontinued Operations---------
Other Adjustments Net32.68M23.26M33.74M95.37M-29.59M15.85M12.04M12.96M0.83M
Sarepta Therapeutics Net Cash from (used by) Operating Activities
Increase (Decrease) in Prop Plant And Equipment-3.4M-25.44M-2.37M-0.1M-1.17M-0.83M-0.93M-0.36M-1.27M
Acquisition Disposition of Subsidiaires--------0.01M-
Increase (Decrease) in Investments13.24M-132.2M-7.89M---0.01M0.11M-0.01M12.7M
Other Cash Inflow (Outflow) from Investment Activities-1.43M-1.38M-1.4M-1.03M-1.12M-1.12M-1.06M-0.84M-0.85M
Sarepta Therapeutics Net Cash from (used by) Invesment Activities
Issuance (Purchase) of Equity Shares130.8M104.24M145.98M178.68M32.38M2.56M47.84M0.08M18.74M
Issuance (Repayment) of Debt Securities17M-0.09M-0.08M-0.08M-0.08M-0.07M-0.07M-0.11M-
Increase (Decrease) in Bank & Other Borrowings---------
Payment of Dividends & Other Cash Distributions---------
Other Cash from (used by) Financing Activities
Sarepta Therapeutics Net Cash from (used by) Financing Activities
Effect of Exchange Rate Changes on Cash---------
Sarepta Therapeutics Net Change in Cash & Cash Equivalents
Cash & Equivalents at Beginning of Year73.55M256.96M187.66M39.9M33.58M48.27M11.19M24.8M20.15M
Cash & Equivalents at Year End80.3M73.55M256.96M187.66M39.9M33.58M48.27M11.19M24.8M
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Years
View Next Years
Get Cash flow for another ticker

Sarepta Therapeutics stock price history provides insight into historical stock price fluctuations, and Sarepta Therapeutics stock comparison chart enables peer comparison. Some of the key terms used in the statement of cash flows are:
  • Sarepta Therapeutics had a Net Change in Cash and Cash Equivalents of $6.75M for the latest year 2015. If a firm is able to grow its cash, it is considered to be a positive signal and could lead to a jump in the Sarepta Therapeutics stock price , albeit too much cash on hand can imply the company has no or limited avenues for growth in which to invest this cash.
  • Cash Flow from operating activities: Operating activities include the core business activities. This line item refers to the cash generated from the same and stood at a negative value of $-149.46M for SRPT.
  • Cash Flow from investment activities: Sarepta Therapeutics generated $167.44M cash due to investment activities. It includes the use of cash outside of normal day to day activities like buying fixed assets, plant and machinery etc.
  • Cash Flow from financing activities: Financing activities include the cash that comes into a company in the form of loans or interest earned or shareholders money, as well as the cash that goes out. Sarepta Therapeutics earned $43.65M from financing activities,in the form of repayment of loans or interest paid, dividend pay-out to shareholders etc.